Inferior Clinical Outcomes of Pediatric Rhabdomyosarcoma in Thailand: A 16-Year Experience in a Single Tertiary Institution
暂无分享,去创建一个
Thirachit Chotsampancharoen | S. Sangkhathat | Pornpun Sripornsawan | Pasuree Sangsupavanich | Songyos Rajborirug | Ploypailin Preechawetchakul
[1] D. Rodeberg,et al. Update on pediatric rhabdomyosarcoma: A report from the APSA Cancer Committee. , 2020, Journal of pediatric surgery.
[2] L. Wexler,et al. Pediatric rhabdomyosarcoma with bone marrow metastasis , 2020, Pediatric blood & cancer.
[3] X. Ni,et al. [Clinical and prognostic analysis of single-center multidisciplinary treatment for rhabdomyosarcoma in children]. , 2019, Zhonghua er ke za zhi = Chinese journal of pediatrics.
[4] Andrew A. Dobitsch,et al. Epidemiology, Incidence, and Survival of Rhabdomyosarcoma Subtypes: SEER and ICES Database Analysis , 2019, Journal of orthopaedic research : official publication of the Orthopaedic Research Society.
[5] D. Rodeberg,et al. Refinement of risk stratification for childhood rhabdomyosarcoma using FOXO1 fusion status in addition to established clinical outcome predictors: A report from the Children's Oncology Group , 2019, Cancer medicine.
[6] Hsiu-Hao Chang,et al. Clinical outcomes of pediatric patients with newly diagnosed rhabdomyosarcoma treated by two consecutive protocols - A single institution report in Taiwan. , 2019, Journal of the Formosan Medical Association = Taiwan yi zhi.
[7] L. Rozek,et al. Childhood cancer incidence and survival in Thailand: A comprehensive population‐based registry analysis, 1990–2011 , 2018, Pediatric blood & cancer.
[8] Kyung-Ja Cho,et al. Clinical and Cytogenetic Profiles of Rhabdomyosarcoma with Bone Marrow Involvement in Korean Children: A 15-Year Single-Institution Experience , 2017, Annals of laboratory medicine.
[9] James R. Anderson,et al. Histology, fusion status, and outcome in metastatic rhabdomyosarcoma: A report from the Children's Oncology Group , 2017, Pediatric blood & cancer.
[10] R. Kapoor,et al. Pediatric rhabdomyosarcoma in India: A single-center experience , 2017, Indian Pediatrics.
[11] S. Sangkhathat. Current management of pediatric soft tissue sarcomas. , 2015, World journal of clinical pediatrics.
[12] H. Xiong,et al. Clinical characteristics and prognosis of childhood rhabdomyosarcoma: a ten-year retrospective multicenter study. , 2015, International journal of clinical and experimental medicine.
[13] Ching-Hon Pui,et al. Toward the Cure of All Children With Cancer Through Collaborative Efforts: Pediatric Oncology As a Global Challenge. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[14] I. Bayram,et al. Replacing actinomycin-D with Carboplatin for newly diagnosed rhabdomyosarcoma. , 2015, Asian Pacific journal of cancer prevention : APJCP.
[15] M. Lai,et al. Incidence of cancer in children aged 0-14 years in Taiwan, 1996-2010. , 2015, Cancer epidemiology.
[16] James R. Anderson,et al. Shorter-duration therapy using vincristine, dactinomycin, and lower-dose cyclophosphamide with or without radiotherapy for patients with newly diagnosed low-risk rhabdomyosarcoma: a report from the Soft Tissue Sarcoma Committee of the Children's Oncology Group. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[17] T. Soe,et al. Singapore rhabdomyosarcoma (RMS) experience: shall we change our practice? , 2014, Annals of the Academy of Medicine, Singapore.
[18] S. Wiangnon,et al. Childhood cancer incidence and survival 1985-2009, Khon Kaen, Thailand. , 2014, Asian Pacific journal of cancer prevention : APJCP.
[19] James R. Anderson,et al. Histologic and clinical characteristics can guide staging evaluations for children and adolescents with rhabdomyosarcoma: a report from the Children's Oncology Group Soft Tissue Sarcoma Committee. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[20] D. Hawkins,et al. Rhabdomyosarcoma: Review of the Children's Oncology Group (COG) soft‐tissue Sarcoma committee experience and rationale for current COG studies , 2012, Pediatric blood & cancer.
[21] Y. Al-Tonbary,et al. Epidemiological Characteristics and Survival Studies of Rhabdomyosarcoma in East Egypt: A Five-Year Multicenter Study , 2012, ISRN oncology.
[22] H. Tamim,et al. Rhabdomyosarcoma Treatment and Outcome at a Multidisciplinary Pediatric Cancer Center in Lebanon , 2012, Pediatric hematology and oncology.
[23] S. Bhatia. Disparities in cancer outcomes: Lessons learned from children with cancer , 2011, Pediatric blood & cancer.
[24] L. Koniaris,et al. Rhabdomyosarcoma in children: a SEER population based study. , 2010, The Journal of surgical research.
[25] S. Wiangnon,et al. Childhood cancer incidence and survival 2003-2005, Thailand: study from the Thai Pediatric Oncology Group. , 2011, Asian Pacific journal of cancer prevention : APJCP.
[26] N. Rezaei,et al. Clinical characteristics and the prognosis of childhood rhabdomyosarcoma in 60 patients treated at a single institute. , 2011, Acta medica Iranica.
[27] James R. Anderson,et al. Vincristine, actinomycin, and cyclophosphamide compared with vincristine, actinomycin, and cyclophosphamide alternating with vincristine, topotecan, and cyclophosphamide for intermediate-risk rhabdomyosarcoma: children's oncology group study D9803. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[28] I. Kim,et al. Initial response to treatment was highly associated with the prognosis of childhood rhabdomyosarcoma: a retrospective analysis of a single center experience in Korea. , 2008, Cancer research and treatment : official journal of Korean Cancer Association.
[29] R. Swaminathan,et al. Childhood cancers in Chennai, India, 1990–2001: Incidence and survival , 2008, International journal of cancer.
[30] James R. Anderson,et al. Prognostic factors in metastatic rhabdomyosarcomas: results of a pooled analysis from United States and European cooperative groups. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[31] S. Ha,et al. Treatment outcome of rhabdomyosarcoma in Hong Kong Chinese children. , 2008, Hong Kong medical journal = Xianggang yi xue za zhi.
[32] H. Hosoi,et al. A review of 331 rhabdomyosarcoma cases in patients treated between 1991 and 2002 in Japan , 2007, International Journal of Clinical Oncology.
[33] James R. Anderson,et al. Analysis of prognostic factors in patients with nonmetastatic rhabdomyosarcoma treated on intergroup rhabdomyosarcoma studies III and IV: the Children's Oncology Group. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[34] E. Habib,et al. Rhabdomyosarcoma: the experience of the pediatric unit of Kasr El-Aini Center of Radiation Oncology and Nuclear Medicine (NEMROCK) (from January 1992 to January 2001). , 2006, Journal of the Egyptian National Cancer Institute.
[35] S. Muzaffar,et al. Rhabdomyosarcoma in Karachi 1998-2002. , 2004, Asian Pacific journal of cancer prevention : APJCP.
[36] James R. Anderson,et al. Age is an independent prognostic factor in rhabdomyosarcoma: A report from the soft tissue sarcoma committee of the children's oncology group , 2004, Pediatric blood & cancer.
[37] James R. Anderson,et al. Intergroup rhabdomyosarcoma study-IV: results for patients with nonmetastatic disease. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[38] James R. Anderson,et al. Rhabdomyosarcoma and Undifferentiated Sarcoma in the First Two Decades of Life: A Selective Review of Intergroup Rhabdomyosarcoma Study Group Experience and Rationale for Intergroup Rhabdomyosarcoma Study V , 2001, Journal of pediatric hematology/oncology.
[39] James R. Anderson,et al. Pretreatment TNM staging of childhood rhabdomyosarcoma , 1997, Cancer.
[40] V. Poliakov,et al. [Rhabdomyosarcoma in children]. , 1980, Pediatriia.
[41] 博之 伊藤,et al. 急激に発生した篩骨洞 rhabdomyosarcoma 症例 , 1979 .
[42] A. V. Kiselev. [Soft tissue sarcomas in childhood]. , 1976, Meditsinskaia sestra.
[43] S. Parlee,et al. This Work Is Licensed under a Creative Commons Attribution-noncommercial 4.0 International License , 2022 .